FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
 									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

					1						Unipariy Act C	71 10-1		_						
1. Name ar Niklaso	2. Issuer Name and Ticker or Trading Symbol Humacyte, Inc. [HUMA]									(Cr	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner									
(Last) 2525 EA	•	(First) (Middle) TH CAROLINA HIGHWAY 54				3. Date of Earliest Transaction (Month/Day/Year) 06/13/2023									X Officer (give title below) Other (s below) President, CEO and Director				·	
(Street) DURHA	M NO	C 27713			4. If Amendment, Date of Original Filed (Month/Day/Year)										Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication														
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																	
		Table	I - N	lon-Deriva	tive S	ecui	ities	Ac	quire	d, Di	sposed of	, or	Bene	ficia	ally Owr	ned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				Execution Date,		∍,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 5)				Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A (D) or)	Price	Reporte Transac (Instr. 3	tion(s)				
Common Stock 06/13/202					3			S		4,875,000(1)		D	\$2.6	10,490,736		I		By Ayabudge LLC		
Common	Stock						П					1,27	0,240		D					
Common Stock														510,161		I		By spouse		
		Tab	le II	l - Derivativ (e.g., pu							oosed of, convertib					d	,			
1. Title of Derivative Conversion or Exercise Price of Derivative Security					Transaction Proceedings of the Code (Instr. 8)		5. Number of Derivative Securited (A) or Disposed of (D) (Instr. 3, 4 and 5)		3				1 4)	8. Price of Derivative Security (Instr. 5)			10. Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amo or Num of Shar	ber						

Explanation of Responses:

1. The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.

Remarks:

/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact

** Signature of Reporting Person

06/15/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.